Head-To-Head Analysis: Anika Therapeutics (NASDAQ:ANIK) vs. Vivos (OTCMKTS:RDGL)

Vivos (OTCMKTS:RDGL) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap finance companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Valuation and Earnings

This table compares Vivos and Anika Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos	$20,000.00	2,789.10	-$2.89 million	($0.01)	-12.30
Anika Therapeutics	$117.05 million	1.39	-$82.67 million	($3.88)	-2.91

Vivos has higher earnings, but lower revenue than Anika Therapeutics. Vivos is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vivos has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Vivos and Anika Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos	0	0	0	0	0.00
Anika Therapeutics	0	0	1	1	3.50

Anika Therapeutics has a consensus target price of $20.00, indicating a potential upside of 76.83%. Given Anika Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Anika Therapeutics is more favorable than Vivos.

Profitability

This table compares Vivos and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos	N/A	N/A	-197.34%
Anika Therapeutics	-59.40%	-2.22%	-1.75%

Insider and Institutional Ownership

91.5% of Anika Therapeutics shares are owned by institutional investors. 18.5% of Vivos shares are owned by company insiders. Comparatively, 9.6% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Anika Therapeutics beats Vivos on 8 of the 15 factors compared between the two stocks.

About Vivos

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.